New regulatory proposals on tobacco questionable on both passage and impact
Will Sarepta finally get approval for eteplirsen?
Merck plays catch-up while Bristol-Myers looks global.
Two drugs are hot on Pfizer’s tail.
Amgen leads the PCSK9-blocker class of cholesterol drugs.
Could a third rejection may be looming for MNKD inhalable insulin?
Idenix files suit atop $9 billion sales estimates for Gilead's Sovaldi
Concerns over Boerhringer Ingelheim plant delay approval of key diabetes agent
Merck, Bristol-Myers and Roche head the race to pioneer PD-1 therapies.
Eli Lilly struggles to gain approval and regain diabetes market share.
Roche’s new deal with Discuva marks major private sector commitment to antibiotic development
New breakthrough designation could help Bristol-Myers compete more quickly with market-leader Gilead.
AbbVie and Bristol-Myers unlikely to catch Gilead in race for oral hep C combination therapy
CEO Pascal Soriot is fighting an uphill battling winning investors on pipeline.
Multiple approaches to depression treatment fail trials
2014 starts a dismal year for Duchenne prospects by Sarepta, Prosensa, PTC and Retrophin
New clinical data from AbbVie spice up hepatitis C market and prospects for the company
Ariad's troubled drug Iclusig undergoes an official return to market.
GSK, Eli Lilly and Sanofi fight for already-crowded diabetes market share
Well-diversified and restructured Roche handles a minor bitopertin setback.